Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.50% -0.08% 208.01M 10252.20
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0% 68.00% 13.45M Upgrade

Basic Info

Investment Strategy
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name ALPS
Prospectus Benchmark Index
S-Network Medical Breakthroughs TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Ryan Mischker 6.51 yrs
Andrew Hicks 5.51 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 28
13.45M
-4.465B Category Low
6.183B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of September 30, 2021

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of October 25, 2021. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2014
2015
2016
2017
2018
2019
2020
YTD
--
27.86%
-27.83%
45.63%
-11.71%
50.30%
21.17%
-9.58%
4.94%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
18.86%
11.13%
20.27%
1.67%
34.87%
9.15%
20.17%
31.47%
5.95%
--
--
--
36.93%
-12.24%
39.64%
52.91%
-7.23%
44.98%
13.58%
-15.45%
43.77%
-15.27%
32.56%
48.33%
-11.62%
15.97%
10.04%
11.78%
30.50%
8.91%
22.31%
32.91%
10.31%
As of October 25, 2021.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (10-26-21) 0%
30-Day SEC Yield (10-22-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of October 22, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of October 22, 2021

Asset Allocation

As of October 22, 2021.
Type % Net % Long % Short
Cash 0.01% Upgrade Upgrade
Stock 99.99% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Legend Biotech Corp ADR 4.47% 52.16 0.89%
Kodiak Sciences Inc 3.47% 111.67 -2.04%
Cerevel Therapeutics Holdings Inc Ordinary Shares 3.41% 39.08 -2.52%
Vir Biotechnology Inc 3.06% 40.27 -2.42%
Alkermes PLC 2.91% 31.52 -0.88%
TG Therapeutics Inc 2.61% 31.69 -1.37%
Iovance Biotherapeutics Inc 2.31% 26.23 0.15%
Karuna Therapeutics Inc 2.26% 134.14 1.48%
Arena Pharmaceuticals Inc 2.14% 57.02 -2.78%
Aurinia Pharmaceuticals Inc 2.09% 30.32 1.61%

News

Headline
Wire
Time (ET)

Basic Info

Investment Strategy
The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Prospectus Objective Specialty - Health
Fund Owner Firm Name ALPS
Prospectus Benchmark Index
S-Network Medical Breakthroughs TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Ryan Mischker 6.51 yrs
Andrew Hicks 5.51 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (10-26-21) 0%
30-Day SEC Yield (10-22-21) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of October 22, 2021

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of October 22, 2021

Fund Details

Key Dates
Inception Date 12/30/2014
Last Annual Report Date 11/30/2020
Last Prospectus Date 3/31/2021
Attributes
Enhanced Index Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No

News

Headline
Wire
Time (ET)